FDC Ltd reported consolidated revenue from operations of 4.65 billion rupees and a net profit of 283 million rupees for the December quarter. The board declared a dividend of 5 rupees per share, reflecting strong fundamentals, operational efficiency, and commitment to shareholder value in the pharmaceutical sector.
FDC Ltd, a leading pharmaceutical company, has announced its financial results for the December quarter of FY26, showcasing steady growth and profitability. The company posted consolidated revenue from operations at 4.65 billion rupees, supported by consistent demand across its product portfolio. Net profit stood at 283 million rupees, highlighting effective cost management and improved margins.
In addition to its earnings, the board declared a dividend of 5 rupees per share, reinforcing its commitment to rewarding shareholders. Analysts note that FDC’s diversified product offerings and focus on operational efficiency have contributed significantly to its sustained performance in a competitive market.
Key highlights from the announcement include
-
Consolidated revenue from operations at 4.65 billion rupees in Q3 FY26
-
Net profit reported at 283 million rupees for the December quarter
-
Board declares dividend of 5 rupees per share
-
Strong demand across pharmaceutical portfolio supported revenue growth
-
Operational efficiency and cost management strengthened profitability
Industry experts emphasize that FDC’s performance reflects its strong fundamentals and adaptability to evolving market dynamics. With continued focus on innovation and expansion, the company is expected to maintain growth momentum in the coming quarters.
Sources: Reuters, Economic Times, Business Standard, Mint